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Identity 
Other names: ARHGEF23, FLJ42780, tgat 
HGNC (Hugo): TRIO 
Location: 5p15.2 
Local order: The human gene maps to chromosome 
5p14-p15.1; between markers D5S2894 and RH45695.  
Gene orientation: forward strand. 
Note: By remodeling the actin cytoskeleton, Rho-
GTPases are involved in many physiological processes 
such as cell motility, proliferation and differentiation in 
different cellular systems. Rho-GTPases cycle betwen 
an inactive GDP-bound state and an active GTP-bound 
state. They are activated by Guanine-nucleotide 
Exchange Factors (GEFs), which often show tissue- 
and/or developmental-specific distribution and 
therefore represent key components to temporally and 
spatially control Rho-GTPase activities. 
The RhoGEF TRIO is a good example for the panel of 
physiological and pathological processes GEFs are 
implicated in, since it participates both in muscle and 
neuronal development and in cancer. TRIO is a 
complex protein harboring two GEF domains (GEF1 
and GEF2), activating the GTPases Rac1/RhoG and 
RhoA, respectively, and thus potentially linking several 
Rho-GTPase signaling pathways in vivo. In 
invertebrates, TRIO plays a central role in cell 
migration and axon guidance, mainly through the 
activation of Rac1 by the GEF1 domain. In mammalian 
cells, TRIO is required for RhoG-mediated neurite 
outgrowth in response to NGF, and is responsible for 
Rac1 activation elicited by the attractive cue Netrin-1 
via its receptor DCC, during axon outgrowth and 
guidance. 
Recently, an oncogenic isoform of TRIO, called Tgat, 
has been identified from adult T-cell leukemia patien  
cells, which encodes only the RhoA-specific GEF 
domain. Tgat induces cell transformation and tumor 
formation in nude mice, mainly via activation of RhoA. 
DNA/RNA 
Note 
The Ensembl Database shows several TRIO transcripts, 
only one of which encodes the full length protein and 
two, which are translated into parts of the protein 
(Figure 1). In addition, 6 splice variants have been 
identified and characterized at the protein level (Figure 
2) (Portales-Casamar et al., 2006). 
Description 
The TRIO gene consists of 58 exons encoding for a 
10244 bp transcript. 
Transcription 
TRIO mRNA shows a ubiquitous expression pattern in 
adult human tissues (Debant et al., 1996). It is also 
present in embryonic tissues, as in mice it is detectable 
starting from around embryonic day 10 (E10) (Portales-
Casamar et al., 2006). 
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Figure 1: Localization of the TRIO gene on human chromosome 5 and exon structure. Figure 2: Genomic organization of the 
splice variants of the TRIO protein. The common exons between TRIO and the isoforms are represented as black boxes, while the 




The human TRIO gene encodes a protein of 3097 
amino acids, with a predicted molecular weight of 
340.6 kD. The TRIO protein harbors distinct domains 
(Figure 3). Six shorter isoforms have been described, 
which are listed in Figure 4 with their respective 
molecular weights. TRIO is a complex protein 
containing three catalytic domains (hence the name 
"TRIO"): two tandem Dbl Homology (DH) - pleckstrin 
homology (PH) domains, and a Serine/Threonine 
kinase domain (Debant et al., 1996). The DH-PH 
module activates the small GTPases of the Rho family 
by mediating guanine nucleotide exchange. The 
DH1PH1 domain (also named GEF1) activates the 
GTPases RhoG and Rac1, while DH2PH2 (GEF2) 
activates RhoA (Bellanger et al., 1998; Blangy et al., 
2000). So far, the kinase domain has not been 
characterized further. In addition to these domains, 
TRIO harbors numerous other motifs, including a 
Sec14 lipid-binding domain (also called CRAL-TRIO 
domain), eight spectrin repeats, two Src Homology 3 
domains (SH3) and an Immunoglobulin domain. The 
presence of these numerous domains suggests that 
TRIO functions as an integrator of multiple upstream 
inputs and as an activator of multiple downstream 
pathways. 
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Figure 3: Domain structure of the TRIO protein: Sec14, domain homologous to S. cerevisiae phosphatidylinositol transfer protein 
(Sec14p); spectrin repeats; DH, Dbl homology domain; PH, pleckstrin homology domain; SH3, Src homology 3 domain; Ig, 
Immunoglobulin-C2 type domain; S/T Kinase, Serine/Threonine Kinase domain. 
 
Figure 4: Isoforms of TRIO are represented schematically, together with their respective molecular weights (on the right). 
 
Expression 
The full length TRIO protein is ubiquitously express d, 
although at a low level, but its shorter isoforms have a 
more specific expression pattern. Isoforms TRIO A, B 
and D are strongly and exclusively expressed in various 
regions of the brain, throughout development (starting 
at E10) and in the adult, while the expression of the
isoform TRIO C is specific to the cerebellum (Portales-
Casamar et al., 2006; Sun et al., 2006). To date, 
Isoform TRIO E has only been detected in human 
neuroblastoma cell lines (Portales-Casamar et al., 
2006). The Tgat isoform has been detected at the 
mRNA level in cells from patients with adult T-cell 
leukemia (ATL) (Yoshizuka et al., 2004). 
Localisation 
TRIO protein is primarily located in the cytoplasm of 
cells, but it is also found partly associated with the 
plasma membrane, as in the case of the TRIO C 
isoform (Sun et al., 2006), or colocalizing with F-actin 
at the tip of the growth cone in PC12 cells (Estrach et 
al., 2002). The link between TRIO and the actin 
cytoskeleton is further strengthened by its interactions 
with the actin-binding proteins Filamin A and Tara 
(Bellanger et al., 2000; Seipel et al., 2001), as well as 
its association with Focal Adhesion Kinase (FAK) 
(Medley et al., 2003). 
Function 
TRIO has originally been identified in human in 1996, 
in a two-hybrid screen using the cytoplasmic fragment 
of the tyrosine phosphatase LAR as bait (Debant et al., 
1996). TRIO is a RhoGEF for the GTPases RhoG/Rac1 
on one hand (via its GEF1 domain) and RhoA on the 
other hand (via its GEF2 domain). TRIO is implicated 
in the regulation of different physiological process , 
most notably in neuronal physiology, but also in 
myogenesis and phagocytosis, processes that all require 
the rearrangement of the actin cytoskeleton. At the 
pathological level, evidence accumulates that TRIO is 
implicated in disease, mainly cancer, most likely by 
regulating actin cytoskeleton dynamics in migrating or 
invasive cells. 
The TRIO Rho-GEF and neuronal physiology 
The first evidence for a role of TRIO in neuronal 
physiology came from genetic analyses of TRIO 
orthologues in Caenorhabditis elegans (unc-73) and in 
Drosophila (D-TRIO), which established the TRIO 
family as a key component of the intracellular signaling 
pathway that regulates axon guidance and cell 
migration, mainly in the nervous system (Steven et al., 
1998; Awasaki et al., 2000; Bateman et al., 2000; Liebl 
et al., 2000; Newsome et al., 2000). 
Gene targeting studies in mouse have then shown that 
TRIO is required for late embryonic development, 
probably by playing essential roles in the development 
of the nervous system and in fetal skeletal muscle 
formation (O'Brien et al., 2000). Consistently, 
mammalian TRIO has been shown to be required for 
RhoG-mediated neurite outgrowth in PC12 cells in 
response to NGF (Estrach et al., 2002). A direct 
interaction between TRIO and the integral membrane 
protein Kidins220/ARMS was further shown in this 
pathway, which might regulate membrane localization 
of TRIO in response to NGF (Neubrand et al., 2010). 
And more recently, a role for TRIO in mediating 
netrin-1-induced axon guidance has been found 
(Briançon-Marjollet et al., 2008). During development 
of the nervous system, Netrin-1 has been shown to 
promote axonal outgrowth through the binding of its 
receptor DCC. The binding of netrin-1 to DCC  
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activates the small GTPase Rac1, through a Rho-GEF 
which had not been identified. Briançon-Marjollet and 
colleagues have shown that TRIO is the GEF 
responsible for this Rac activation signal elicited by 
Netrin-1/DCC, during axon outgrowth and guidance 
(Briançon-Marjollet et al., 2008). Further studies have 
also shown that TRIO regulates the organization of 
neuronal clusters in the hindbrain in vivo (Backer et al., 
2007). 
The ultimate evidence for the essential role of TRIO in 
the development of the nervous system has been 
brought recently with the generation and 
characterization of mice with a neural specific knock-
out of TRIO (TrioNKO) (Peng et al., 2010). About 
90% of TrioNKO mice died within 1 day after birth. 
Surviving mice showed a reduced body weight and 
smaller brain, with defective cerebella and severe signs 
of ataxia, probably due to the absence of granule cells
in the internal granule cell layer (Peng et al., 2010). 
TRIO and muscle development 
In addition to neuronal defects, TRIO KO mice show 
also defects in secondary myogenesis, suggesting a role 
for TRIO in this late developmental process (O'Brien et 
al., 2000). More recently, Charrasse and colleagues 
have clarified this role using C2C12 cells (Charrasse et 
al., 2007). Myoblast fusion requires M-Cadherin-
dependent Rac1 activation. It appears that TRIO is 
complexed with Rac1 and M-Cadherin prior to 
myoblast fusion, leading to Rac1 activation. In contrast 
TRIO knockdown by shRNA inhibits this fusion 
process. 
TRIO and phagocytosis of apoptotic cells 
TRIO is implicated in phagocytosis of apoptotic cells 
both in mammals and in worms (deBakker et al., 2004).  
In mammals, the ELMO/DOCK180/CrkII complex is 
able to activate Rac and to induce cytoskeletal 
modifications leading to phagocytosis. TRIO activates 
RhoG, which in turn interacts with and activates this 
ELMO/DOCK180/Rac complex. This pathway is 
conserved in C.elegans. 
TRIO and cancer 
This topic is dealt with in the following section 
concerning diseases TRIO is implicated in. 
Homology 
TRIO has originally been identified in human in 1996, 
as an interactor of the tyrosine phosphatase LAR 
(Debant et al., 1996). Since then, TRIO orthologs have 
been identified in invertebrates, C. elegans and 
Drosophila, called Unc-73 and DTRIO respectively 
(Steven et al., 1998; Lin and Greenberg, 2000). In 
mammals, there exists a paralog of TRIO, called 
Kalirin that was originally identified in rat (Alam et al., 
1997). Interestingly, the structural organization of 
TRIO family members is very well conserved through 
evolution. Human TRIO and human Kalirin share 
61.4% identity, and both show a similar identity to 
DTRIO (43.6% and 43.2% respectively) and to Unc-73 
(29.3% and 29.6% respectively). Identity between 
orthologs is even higher if the domains are considere  
separately (up to 92% for TRIO and Kalirin GEF1 for
example). 
TRIO function is also conserved through evolution, 
since all orthologs are implicated in neuronal specific 
functions, ranging from neuronal development to cell




A systematic sequencing of cancer genomes led to the 
identification of more than 1000 somatic mutations i  
the coding exons of 518 protein kinase genes. In this 
study, 9 mutations have been found in the TRIO gene 
(Greenman et al., 2007).  
 
Figure 5: Schematic representation of the TRIO protein annotated with the mutations found in various cancers. 
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More detailed information of this study can be found 





A systematic sequencing study of cancer genomes 
obtained from 210 diverse human cancers (primary 
tumors and immortalized cell lines) has been performed 
to find possible mutations in the 518 kinases of the
human genome (Greenman et al., 2007). The screened 
cancers included breast, lung, colorectal, gastric, testis, 
ovarian, renal, melanoma, glioma and acute 
lymphoblastic leukemia. Over 1000 somatic mutations 
were detected in 321 kinases, including mostly single 
substitutions, and a few small insertions, deletions r 
complex changes. Statistical analysis allowed 
determining a factor indicating whether these mutations 
are "driver" or "passenger" mutations. TRIO having a 
kinase domain in its C-terminus was among the genes 
sequenced in this study. Nine mutations were identifi d 
in the TRIO gene, spanning the whole sequence (Figure 
5). Interestingly, 6/9 mutations lied within the catalytic 
domains of TRIO (both DH-PH domains and the kinase 
domain). The cancer types these mutations were found 
in were diverse, with a prevalence of melanoma 
however. The "driver/passenger" selection pressure 
factor was 0.78 for TRIO, suggesting that the mutations 




In the past 5-6 years, a number of publications have 
emerged in the literature implicating TRIO as a 
potential cancer gene. Most notably, in many different 
cancer types (see list below), copy number gains and 
high-level amplifications of the short arm of 
chromosome 5 (band 5p) are frequently observed. This
suggests the presence of driver genes on 5p involved in 
malignant progression. Interestingly, the TRIO gene 
maps precisely to this region. 
Glioblastoma 
Disease 
It has been shown previously that the small GTPases 
Rac1 and Rac3 play a role in both migration and 
invasion of malignant gliomas. In order to identify Rac-
GEFs that could mediate glioblastoma invasiveness, 
Salhia and colleagues performed gene expression 
profiling on a brain tumor expression database and 
identified the GEFs TRIO, Ect2 and Vav3 as being 
expressed at higher levels in glioblastoma versus low-
grade glioma (Salhia et al., 2008). The expression of 
these GEFs is also associated with poor patient 
survival. Real time qPCR and immunohistochemical 
analyses on an independent set of tumors confirmed 
this overexpression in glioblastoma compared to either 
nonneoplastic brain or low-grade gliomas. Moreover, 
siRNA silencing of TRIO, Ect2 or Vav3 suppressed 
glioblastoma cell migration and invasion. Depletion of 
TRIO or Ect2 also significantly reduced the rate of 
glioblastoma cell proliferation, whereas cell survival 
was not compromised (Salhia et al., 2008). 
Prognosis 
High expression of TRIO, Ect2 and Vav3 in 
glioblastoma patients (GBM) is associated with poor 
patient outcome. According to Kaplan-Meyer survival 
curves, two distinct patients' clusters could be formed, 
the first with a long-term median survival, the second 
with a short-term median survival. Expression of the
three RhoGEFs was significantly higher in the second 
cluster, indicating a relationship between GEF 




Lane and co-authors investigated the expression and 
prognostic value of the RhoGEFs TRIO, Vav1 and 
Tiam-1 in human breast cancer (Lane et al., 2008). 
Comparison of breast tumor tissue versus normal 
background tissue by real time qPCR and 
immunohistochemistry revealed high expression levels 
of TRIO, Vav1 and Tiam-1 in breast tumors, reaching a 
level of significance for TRIO (P=0.013). TRIO levels 
also increased significantly in patients with poor 
predictive outcome (Nottingham Prognosis Index), 
while Tiam-1 levels were significantly higher in tumor 
tissue from patients who died from breast cancer 
compared with those who survived (Lane et al., 2008). 
TRIO could therefore be very useful as a prognostic 
factor in breast cancer. 
Two other related studies looked at the gene expression 
signatures of breast epithelial cells exposed to 
estrogens and parathion (an agricultural pesticide) 
(Calaf and Roy, 2007a; Calaf and Roy, 2007b). There 
exists indeed an association between breast cancer d 
exposure to environmental substances. Parathion alone 
or in combination with 17beta-estradiol (E2) induced 
malignant transformation of MCF-10F cells, which was 
confirmed by anchorage independent growth and 
invasive capabilities. Parathion alone significantly 
elevated the expression of a number of proteins, 
including TRIO (1.8-fold), but combination with E2 
induced an even stronger increase (2 fold over E2 alone 
treated cells, in the case of TRIO) (Calaf and Roy, 
2007a). 
Prognosis 
TRIO levels increased significantly in patients with 
poor prognosis index (Lane et al., 2008). This suggests 
that aberrant regulation of Rho GTPase activities by 
GEFs may have an important prognostic value in breast 
cancer. 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(6)  495 
Soft tissue sarcoma 
Disease 
Comparative Genomic Hybridization (CGH) array 
studies have shown that copy number gains and high-
level amplifications of the short arm of chromosome 5 
(band 5p15) are often observed in soft tissue sarcomas 
with complex genomic profiles, which aggressive 
mesenchymal tumors (Adamowicz et al., 2006). 
Adamowicz et al. analyzed 34 soft tissue sarcomas (10 
pleiomorphic liposarcomas (LPs) [PL-LP], 8 
dedifferentiated LPs [DD-LP], 6 malignant fibrous 
histiocytomas [MFH], and 10 peripheral nerve sheath 
tumors [MPNST]) using cDNA microarray including 
418 BAC clones, to precisely identify the genes that are 
amplified. Amongst other genes, TRIO was 
consistently found overexpressed in all cases, as 
confirmed by real-time quantitative PCR. In contrast, 
NKD2 and IRX2 genes, which are involved in the Wnt 
developmental pathway, were expressed only in 
MPNSTs. The mRNA expression level of TRIO, 
NKD2 and IRX2 strongly correlated with the gene 
copy number. In conclusion, in soft tissue sarcomas, 
TRIO was highly amplified and up-regulated in a gene-
dosage dependent manner. Thus the TRIO gene 
represents a candidate target of 5p amplifications in 
soft tissue sarcomas and might play a crucial role 
during the progression of the disease (Adamowicz et 
al., 2006). 
Urinary bladder cancer 
Disease 
Like in soft tissue sarcomas, lung cancer or cervical 
cancer, 5p amplification seems to be related to tumor 
progression in urinary bladder cancer (Zheng et al., 
2004; Mhawech-Fauceglia et al., 2006). Zheng and 
colleagues analyzed 7 genes located to 5p15.31-5p15.1 
by FISH (Fluorescent in situ hybridization) using a 
tissue microarray, containing samples from tumors and 
cell lines with known 5p amplifications. Amplification 
frequency was highest for TRIO, which maps to 
5p15.2. Analysis of over 2000 bladder tumors showed 
that TRIO amplification was strongly associated with 
invasive tumor phenotype, high tumor grade and rapid 
tumor cell proliferation. However, TRIO amplification 
was not associated with poor prognosis. Using RNA in 
situ hybridization (RISH) the authors confirmed that 
mRNA expression level of TRIO strongly correlated 
with the gene copy number. This study suggests TRIO 
as an oncogene candidate within this amplicon and a 
potential role for TRIO in bladder cancer progression 
(Zheng et al., 2004). 
Cervical cancer 
Disease 
Two independent studies performed on cervical cancer 
samples identified the TRIO gene as significantly 
upregulated in this cancer type (Kloth et al., 2007; Ng 
et al., 2007). The first study aimed at identifying genes 
showing high-frequency copy number-driven changes 
in expression in cervical squamous cell carcinoma 
(SCC) that would thus contribute to the biology of the 
disease (Ng et al., 2007). To identify such potential 
oncogenes, CGH array and qPCR were performed on 
36 primary samples and 10 cell lines. The most 
commonly occurring regions of copy number gain that 
showed amplification were 5p15.2-14.3 and 5p13.3-
13.1. Gene copy numbers were significantly associated 
with expression levels for three candidate oncogenes: 
OSMR, TRIO and PDZK3 (Ng et al., 2007). FISH 
analysis on a tissue microarray of 110 primary cervi al 
SCC samples revealed copy number gain frequencies 
of 54.5% for TRIO. Survival analysis (Kaplan-Meier) 
correlation revealed only a correlation for OSMR and 
PDZK3 in adversely influencing patient survival. TRIO 
gain did not influence clinical outcome. 
In the second study, 10 cervical cancer cell lines w re 
analyzed by CGH array and SNP array (single 
nucleotide polymorphism) (Kloth et al., 2007). This 
showed an overall concordance in detection of the same 
areas with copy number alterations (CNA). Regions 
frequently targeted by CNA were found with 
amplification of 5p and 20q and loss of 8p, as 
confirmed by FISH. At chromosome 5, there was a 
significant correlation between copy number and gene 
expression. Genes were significantly upregulated in 
cell lines with amplifications as compared to cell lines 
without amplifications. For 3 genes, among which 
TRIO, expression differences were confirmed by real-
time quantitative PCR (Kloth et al., 2007). 
Oral cancer 
Disease 
Array CGH technology was applied to 20 clinical 
samples of oral squamous cell carcinoma (OSCC) 
(Baldwin et al., 2005), which is the most common head 
and neck neoplasm. This allowed the identification of 
genomic modifications ranging from whole 
chromosome arm, segmental or gene-size alterations. 
Amongst others, Baldwin and colleagues found the 
presence of several novel frequent submegabase 
alterations, such as a 0.58Mb gain at 5p15.2, containi g 
the TRIO gene (in 9/20 cases). TRIO transcript levels 
were compared in 4 OSCCs samples and 7 normal 
specimens by RT-PCR, and this showed that TRIO 
expression was significantly higher in the cancer 
samples.  
This is the first report of the microamplification of the 
TRIO locus in oral cancer, as evidenced by tile-path 
array CGH (Baldwin et al., 2005). Deregulation of 
TRIO at the transcriptional level shows the biological 
significance of this locus. 
Esophageal squamous cell carcinoma 
Disease 
A very recent study was performed on patients with 
esophageal squamous cell carcinoma (ESCC) exposed 
to tobacco and betel quid in India (to evaluate 
environmental risk factor contributions) 
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(Chattopadhyay et al., 2010). 10K single nucleotide 
polymorphism (SNP) array on 20 tissue samples 
allowed the identification of 22 amplified regions and 
16 deleted regions. Among the relevant candidate gen s 
located on amplified regions was TRIO (5p15.2) 
(Chattopadhyay et al., 2010). 
Lung cancer 
Disease 
A. Small cell lung carcinoma (SCLC): Like in other 
cancer types, genomic amplification of regions on 
chromosome arm 5p has been observed frequently in 
small cell lung carcinoma (SCLC) (Coe et al., 2005). 
To identify candidate genes on this chromosome arm, 
Coe and colleagues developed a high-resolution BAC 
CGH array for chromosome 5p and examined a panel 
of 15 SCLC cell lines. This allowed fine mapping of 
regional copy number aberrations, and allowed the 
identification of previously undetected microdeletions 
and the identification of TRIO and ANKH as novel 
putative oncogenes. FISH confirmed these 
amplifications (in 6/15 cell lines). However, the 
biological relevance of TRIO and Ankh to SCLC 
remains to be explored. 
B. Non-small cell lung cancer (NSCLC): Using 
genomic profiling of pre-invasive alterations, Garnis 
and co-authors identified multiple early genetic events 
on chromosome 5p in lung cancer progression (Garnis 
et al., 2005). Using a high-resolution 5p-specific 
genomic array, they discovered 9 novel minimal 
regions of loss and gain in bronchial carcinoma in situ
(CIS) samples, which are pre-invasive. Within these 
regions they identified 2 candidate genes novel to lung 
cancer, TRIO, which was differentially expressed in 
tumors, and GDNF, which is normally expressed 
during lung development. Real-time quantitative PCR 
performed on 8 paired normal and squamous cell 
carcinoma (SqCC) samples showed an overexpression 
of the TRIO transcript in 6/8 pairs. This expression 
pattern was confirmed by additional semi-quantitative 
RT-PCR on 13 more samples, showing significant 
overexpression of TRIO. This concordance of copy 
number increase and overexpression in tumor samples 
strongly suggests a role for TRIO in SqCC, while its 
frequent amplification in pre-invasive lesions (CIS) 
suggests its early involvement in tumorigenesis. 
Acute adult T-cell leukemia (ATL) 
Disease 
An alternative splice variant of TRIO with 
transforming properties has been identified from 
patients with adult T-cell leukemia (ATL) (Yoshizuka 
et al., 2004). Using a cDNA library built from ATL 
patients' cells, Yoshizuka and colleagues isolated one
gene with transforming properties in NIH 3T3 
fibroblasts. This gene turned out to be an alternative 
splice variant of TRIO, harboring only the catalytic DH 
domain activating RhoA and a unique 15 amino acid C-
terminal sequence (Yoshizuka et al., 2004). 
Overexpression of Tgat induced cell transformation in 
NIH 3T3 fibroblasts (foci formation, growth in soft 
agar) and tumor formation in nude mice. This required 
the presence of both protein domains. Tgat has been 
proposed to enhance tumor invasion by stimulating 
Matrix MetalloProteinases (MMPs) via the RECK 
protein (Mori et al., 2007) and by activating the 
transcription factor NF-kappaB, which plays a crucial 
role in tumorigenesis, including ATL (Yamada et al., 
2007). 
Interestingly, a recent peptide inhibitor screening 
strategy has identified one peptide, TRIPE32G, which 
specifically inhibits Tgat GEF activity in vitro and 
significantly reduces Tgat-induced RhoA activation 
and foci formation. Furthermore, subcutaneous 
injection of cells expressing Tgat and TRIPE32G into 
nude mice reduces the formation of Tgat-induced 
tumors. This demonstrates that this peptide is a potent 
inhibitor that can be used to interfere with Tgat 
functions in vivo (Bouquier et al., 2009). 
Oncogenesis 
Overexpression of Tgat in NIH 3T3 fibroblasts induced 
foci formation, growth in soft agar, and, upon injection 
into nude mice, tumor formation. 
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